BSD Announces Hyperthermia Featured as the Fourth Pillar in Cancer Treatment at Annual Meeting of the German Cancer Societ

SALT LAKE CITY--(BUSINESS WIRE)-- BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (, a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that hyperthermia was featured at the annual meeting of the German Cancer Society (DKK [Deutscher KrebsKongress]), which was held in Berlin, Germany, February 20-25, 2012. The DKK meeting is an interdisciplinary, scientific meeting focusing on progress in cancer treatment. Focused symposia presented current scientific highlights to more than 4000 participants.

An integral part of the DKK meeting was a symposium presented by the Interdisciplinary Working Group on Hyperthermia (IAH Interdisziplinäre Arbeitsgruppe für Hyperthermie) that included 9 hyperthermia presentations. Several ongoing clinical studies were presented: a study on hyperthermia and radiation treatment of recurrent rectal cancer, sponsored by the University Medical School (UMS) of Erlangen, Germany, and a study on hyperthermia and chemotherapy treatment of primary pancreatic cancer, sponsored by the UMS of Munich, Germany.

An update of the results of the successful EORTC (European Organization for Research and Treatment of Cancer) sponsored clinical study on the use of hyperthermia and chemotherapy to treat high-risk soft tissue sarcoma was also provided to the participants. Munich UMS was the principal investigator for the sarcoma study. All of these studies utilized the BSD-2000 Hyperthermia System to deliver hyperthermia.

BSD’s line of hyperthermia products was featured at its technical exhibition booth at the Congress, which focused on state-of-the-art medical technology and drugs. "A significant number of international medical luminaries visited our booth," stated Dr. Gerhard Sennewald, CEO of Dr. Sennewald Medizintechnik GmbH, BSD’s European distributor. "There was an overwhelming interest in BSD’s top-of-the-line BSD-2000•3D/MR magnetic resonance image-guided hyperthermia system. These systems are already in clinical use at five German University Medical Schools in Berlin, Munich, Erlangen, Duesseldorf and Tuebingen."

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market and well-established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical's website at

Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.


BSD Medical Corporation
Dennis Gauger, 801-972-5555
[email protected]
fax: 801-972-5930

KEYWORDS:   United States  Europe  North America  Germany  Utah

INDUSTRY KEYWORDS:   Health  Hospitals  Medical Devices  Oncology  Radiology  General Health